Onglyza is a medicine containing the active ingredient(s) saxagliptin. On this page you will find out more about Onglyza, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: saxagliptin
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Onglyza 5 mg film-coated tablet, 28
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Add-on combination: ONGLYZA is indicated in patients with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicines, when these together with diet and exercise, do not provide adequate glycaemic control (see Clinical Trials and Precautions for available data on different add-on combination therapies).,Initial combination: ONGLYZA is indicated for use as initial combination therapy with metformin, in patients with type 2 diabetes mellitus, to improve glycaemic control as an adjunct to diet and exercise, when dual saxagliptin and metformin therapy is appropriate (i.e. high initial HbA1c levels and poor prospects for response to monotherapy).
Table of characteristics
Pink, biconvex, round, tablets, 5 printed one side and 4215 on reverse
Images are the copyright of the Pharmacy Guild of Australia
|Dosage Form||Tablet, film coated|
|Route of administration||Oral|
28: Prescription Only Medicine, or Prescription Animal Remedy
7: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 2 results
Onglyza Tablets - myDr.com.au
Onglyza Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Tablets Medication for type 2 diabetes People with type 2 diabetes are often given medications including insulin to help control their blood glucose levels
Read more on Diabetes Australia website
Found 0 results